Trial 13NHL-16-1


Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell Lymphoma

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Kevin Kelly, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Christine Duran, D.M., Ibrahim Syed, Coordinator, Ibrahim Syed, D.M., Sondra Ortiz, Coordinator, Anastasia Martynova, D.M., Donna Fernando, Coordinator, Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.